Effect of preeclampsia on placental function: influence of sexual dimorphism, microRNA's and mitochondria.

L. Myatt,Sribalasubashini Muralimanoharan,A. Maloyan

DOI: https://doi.org/10.1007/978-1-4939-1031-1_12

Advances in experimental medicine and biology

Abstract:

What problem does this paper attempt to address?

Analysis of the Efficacy of Transcatheter Arterial Infusion Chemotherapy in the Treatment of Pancreatic Carcinoma

Chunhui Nie,Yuelin Zhang,Guanhui Zhou,Tanyang Zhou,Tongyin Zhu,Baoquan Wang,Shengqun Chen,Hongliang Wang,Ziniu Yu,Li Jing,Junhui Sun

DOI: https://doi.org/10.1016/j.jimed.2020.10.005

2021-01-01

Journal of Interventional Medicine

Abstract:OBJECTIVE:To evaluate the clinical efficacy of infusion of gemcitabine (GEM) and fluorouracil (5-FU)through the celiac artery and superior mesenteric artery in the treatment of pancreatic carcinoma (PC).METHODS:We analyzed 20 patients diagnosed clinically or pathologically with PC, without metastases, who had an estimated survival duration of >3 months in our department from May 2009 to December 2014. Nine patients were treated directly without surgical resection of the tumor, while the other 11 patients were treated after surgery. In all patients, the femoral artery was punctured using the Seldinger technique, and a catheter was placed in the opening of the celiac artery or the superior mesenteric artery. We administered 500 mg/m2 GEM and 500 mg/m2 5-FU. Observational data included data on clinical efficacy and survival rates during the follow-up period of 3-72 months.RESULTS:Twenty patients were treated 85 times with transcatheter arterial infusion chemotherapy (TAI). The survival rates were 80%, 40%, 35%, 20%, 10%, and 5% at 3, 6, 12, 24, and 72 months, respectively.CONCLUSION:TAI chemotherapy with GEM and 5-FU may be a therapeutic option for the treatment of PC.
Intratumoral Radiofrequency Hyperthermia-Enhanced Direct Chemotherapy of Pancreatic Cancer

Zhibin Bai,Yaoping Shi,Jianfeng Wang,Longhua Qiu,Eric J. Monroe,Gaojun Teng,Feng Zhang,Xiaoming Yang

DOI: https://doi.org/10.18632/oncotarget.12295

2016-01-01

Oncotarget

Abstract:Purpose: To investigate the technical feasibility of using ultrasound-guided intratumoral radiofrequency hyperthermia (RFH) to enhance local chemotherapy of rat orthotopic pancreatic cancers.Materials and Methods: Orthotopic pancreatic cancer masses were established by inoculating luciferase/mCherry labeled-pancreatic cancer cells into the pancreatic tails of Lewis model rats via a laparotomy approach. Twenty-four rats with pancreatic cancer and 24 mice with subcutaneous pancreatic cancer xenografts in four study groups (n = 6/group) received various treatments: i) combination therapy of intratumoral MR imaging-heating-guidewire- mediated RFH (42 degrees C) plus local chemotherapy (gemcitabine); ii) intratumoral chemotherapy alone; iii) RFH alone; and (iv) phosphate-buffered saline (PBS). Transcutaneous ultrasound imaging was used to guide the treatment and subsequently follow changes in tumor sizes. Bioluminescence optical imaging was performed to follow photon signal changes. Sonographic and optical findings were correlated with histology at 14 days.Results: Optical imaging demonstrated a significantly decreased bioluminescence signal in mice with combination therapy group, compared with the other control groups (0.51 +/- 0.18 VS 1.6 +/- 0.4 VS 3.18 +/- 0.9 VS 3.5 +/- 0.96, p < 0.05). Ultrasound imaging showed the smallest tumor volumes of both mice and rat group with the combination therapy, compared with other control groups (0.62 +/- 0.16 VS 1.25 +/- 0.19 VS 2.28 +/- 0.25 VS 2.64 +/- 0.26, p < 0.05) and (0.75 +/- 0.18 VS 1.31 +/- 0.30 VS 1.61 +/- 0.28 VS 1.72 +/- 0.28, p < 0.05). Both imaging findings were confirmed by histologic correlation.Conclusion Intratumoral RFH can augment the chemotherapeutic effect in an orthotopic pancreatic cancer model.
A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Jing Hu,Gang Zhao,Hong-Xia Wang,Lei Tang,Ying-Chun Xu,Yue Ma,Feng-Chun Zhang

DOI: https://doi.org/10.1186/1756-8722-4-11

IF: 28.5

2011-01-01

Journal of Hematology & Oncology

Abstract:BACKGROUND:The objectives of the present study are to investigate the efficacy and safety profile of gemcitabine-based combinations in the treatment of locally advanced and metastatic pancreatic adenocarcinoma (LA/MPC).METHODS:We performed a computerized search using combinations of the following keywords: "chemotherapy", "gemcitabine", "trial", and "pancreatic cancer".RESULTS:Thirty-five trials were included in the present analysis, with a total of 9,979 patients accrued. The analysis showed that the gemcitabine-based combination therapy was associated with significantly better overall survival (OS) (ORs, 1.15; p = 0.011), progression-free survival (PFS) (ORs, 1.27; p < 0.001), and overall response rate (ORR) (ORs, 1.58; p < 0.001) than gemcitabine monotherapy. Similar results were obtained when the gemcitabine-fluoropyrimidine combination was compared with gemcitabine, with the OS (ORs, 1.33; p = 0.007), PFS (ORs, 1.53; p < 0.001), and ORR (ORs 1.47, p = 0.03) being better in the case of the former. The OS (ORs, 1.33; p = 0.019), PFS (ORs, 1.38; p = 0.011), and one-year survival (ORs, 1.40; p = 0.04) achieved with the gemcitabine-oxaliplatin combination were significantly greater than those achieved with gemcitabine alone. However, no survival benefit (OS: ORs, 1.01, p = 0.93; PFS: ORs, 1.19, p = 0.17) was noted when the gemcitabine-cisplatin combination was compared to gemcitabine monotherapy. The combinations of gemcitabine and other cytotoxic agents also afforded disappointing results. Our analysis indicated that the ORR improved when patients were treated with the gemcitabine-camptothecin combination rather than gemcitabine alone (ORs, 2.03; p = 0.003); however, there were no differences in the OS (ORs, 1.03; p = 0.82) and PFS (ORs, 0.97; p = 0.78) in this case.CONCLUSIONS:Gemcitabine in combination with capecitabine or oxaliplatin was associated with enhanced OS and ORR as compared with gemcitabine in monotherapy, which are likely to become the preferred standard first-line treatment of LA/MPC.
Treatment of Advanced Pancreatic Cancer by Transarterial Infusion of Gemcitabine

Liu Lingxiao,Wang Jianhua,Wang Xiaolin

DOI: https://doi.org/10.3969/j.issn.1006-5741.2007.03.014

2007-01-01

Abstract:Purpose:To evaluate the efficacy of transarterial infusion combined gemcitabine protocol and conventional protocol in the treatment of advanced pancreatic cancers.Materials and Methods:To retrospectively analyze the clinical effectiveness of transarterial infusion chemotherapy of combined gemcitabine group and conventional group in the treatment of 65 patients with advanced pancreatic can- cers.Results:The tumor response rate was 32.7% in 65 cases.The clinical benefit response rate(CBR) was 56.9%.Median survival time for all patients was 9.0 months,the cumulative 3,6,9,12 months sur- vival rates were 90.8%、72.6%、45.6% and 28.7%,respectively.Median survival time for gemcitabine group was 11.0 months,the cumulative 3,6,9,12 months survival rates were90.6%、80.7%、57.1%、47.1%.A decrease(over 50%)of CA199 was observed in 14 cases(51.9%).Median survival time for con- ventional group was 8.0 months,the cumulative 3,6,9,12 months survival rates were90.9%、63.9%、33.6%、10.7%.A decrease(over 50%)of CA199 was observed in 13 cases(44.8%).The CBR in cases with pancreatic cancers of the head(Median survival time was 10.0 months)was 68.3%,which was obviously higher than pancreatic cancers of the distal region(Median survival time was 7.0 months)37.5%(P<0.01).Median survival time for 42 patients combined with chemoembolization was 9.0 months,a little longer than the patients with pure transarterial infusion treatment.Conclusion:The transarterial in- fusion chemotherapy combined with gemcitabine can provide patients who had advanced pancreatic cancer with higher CBR and longer median survival time,especially in pancreatic cancers of the head.Treated combined with chemoembolization to the cases with liver metastasis can mildly improved median survival time compared with pure transarterial infusion chemotherapy.
A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer

Melika Rezaee,Jing Wang,Mehdi Razavi,Gang Ren,Fengyan Zheng,Ahmed Hussein,Mujib Ullah,Avnesh S Thakor

DOI: https://doi.org/10.1038/s41598-019-52490-1

2019-11-04

Abstract:Systemic chemotherapy is the first line treatment for patients with unresectable pancreatic cancer, however, insufficient drug delivery to the pancreas is a major problem resulting in poor outcomes. We evaluated the therapeutic effects of targeted intra-arterial (IA) delivery of gemcitabine directly into the pancreas in an orthotopic mouse model of pancreatic cancer. Nude mice with orthotopic pancreatic tumors were randomly assigned into 3 groups receiving gemcitabine: systemic intravenous (IV) injection (low: 0.3 mg/kg and high: 100 mg/kg) and direct IA injection (0.3 mg/kg). Treatments were administered weekly for 2 weeks. IA treatment resulted in a significantly greater reduction in tumor growth compared to low IV treatment. To achieve a comparable reduction in tumor growth as seen with IA treatment, gemcitabine had to be given IV at over 300x the dose (high IV treatment) which was associated with some toxicity. After 2 weeks, tumor samples from animals treated with IA gemcitabine had significantly lower residual cancer cells, higher cellular necrosis and evidence of increased apoptosis when compared to animals treated with low IV gemcitabine. Our study shows targeted IA injection of gemcitabine directly into the pancreas, via its arterial blood supply, has a superior therapeutic effect in reducing tumor growth compared to the same concentration administered by conventional systemic injection.
Diffusion‐weighted MRI Monitoring of Pancreatic Cancer Response to Radiofrequency Heat‐enhanced Intratumor Chemotherapy

Tong Zhang,Feng Zhang,Yanfeng Meng,Han Wang,Thomas Le,Baojie Wei,Donghoon Lee,Patrick Willis,Baozhong Shen,Xiaoming Yang

DOI: https://doi.org/10.1002/nbm.3014

2013-01-01

NMR in Biomedicine

Abstract:The aim of this study was to evaluate the feasibility of using diffusion-weighted MRI to monitor the early response of pancreatic cancers to radiofrequency heat (RFH)-enhanced chemotherapy. Human pancreatic carcinoma cells (PANC-1) in different groups and 24 mice with pancreatic cancer xenografts in four groups were treated with phosphate-buffered saline (PBS) as a control, RFH at 42 °C, gemcitabine and gemcitabine plus RFH at 42 °C. One day before and 1, 7 and 14 days after treatment, diffusion-weighted MRI and T2 -weighted imaging were applied to monitor the apparent diffusion coefficients (ADCs) of tumors and tumor growth. MRI findings were correlated with the results of tumor apoptosis analysis. In the in vitro experiments, the quantitative viability assay showed lower relative cell viabilities for treatment with gemcitabine plus RFH at 42 °C relative to treatment with RFH only and gemcitabine only (37 ± 5% versus 65 ± 4% and 58 ± 8%, respectively, p < 0.05). In the in vivo experiments, the combination therapy resulted in smaller relative tumor volumes than RFH only and chemotherapy only (0.82 ± 0.17 versus 2.23 ± 0.90 and 1.64 ± 0.44, respectively, p = 0.003). In vivo, 14-T MRI demonstrated a remarkable decrease in ADCs at day 1 and increased ADCs at days 7 and 14 in the combination therapy group. The apoptosis index in the combination therapy group was significantly higher than those in the chemotherapy-only, RFH-only and PBS treatment groups (37 ± 6% versus 20 ± 5%, 8 ± 2% and 3 ± 1%, respectively, p < 0.05). This study confirms that it is feasible to use MRI to monitor RFH-enhanced chemotherapy in pancreatic cancers, which may present new options for the efficient treatment of pancreatic malignancies using MRI/RFH-integrated local chemotherapy.
The Underlying Molecular Mechanism of Intratumoral Radiofrequency Hyperthermia-Enhanced Chemotherapy of Pancreatic Cancer

Liangcai Zhao,Yiming Zhou,Zhibin Bai,Feng Zhang,Xiaoming Yang

DOI: https://doi.org/10.1016/j.jimed.2022.02.002

2022-01-01

Journal of Interventional Medicine

Abstract:Background:To investigate the underlying molecular mechanisms of radiofrequency hyperthermia (RFH)-enhanced direct chemotherapy of pancreatic cancers.Method:Rat ductal PaCa cell line DSL-6A/C1 and orthotopic pancreatic cancers of Lewis rats were divided into four study groups with various treatments: i) phosphate-buffered saline (PBS) as a control; ii) RFH alone; iii) intratumoral chemotherapy alone (gemcitabine); and (iv) combination therapy of gemcitabine plus intratumoral RFH at 42 °C for 30 min. In the in-vitro confirmation experiments, the viability and apoptosis of DSL-6A/C1 cells in each treatment group were evaluated using cell live/dead staining, flow cytometry, and Western blot. In the in vivo validation experiments, related proteins were evaluated by immunohistochemistry (IHC) staining of tumors.Results:Of the in-vitro experiments, the lowest cell viability and more apoptotic cells were shown in the group with combination therapy compared to other treatments. Western blot data showed elevated Bax/Bcl-2, Caspase-3, and HSP70 expressions in DSL cells with combination therapy, compared to other treatments. Of the in vivo experiments, IHC staining detected the significantly increased expressions of HSP70, IL-1β, TNF-ɑ, Bax, and Caspase-3 in pancreatic cancer tissues of the animal group treated by combination therapy of gemcitabine with RFH.Conclusion:Molecular imaging-guided interventional RFH can significantly enhance the chemotherapeutic effect on pancreatic cancers via potential molecular mechanisms of up-regulating Bax/caspase-3-dependent apoptosis pathways.
Intrabiliary Radiofrequency-Enhanced Local Chemotherapeutic Deposit in Bile Duct Walls Using a Needle-Integrated Balloon Catheter: A Feasibility Study on Survival Pigs

F Zhang,J Gao,Y JIN,S Jingjing,F Xiong,X Yang

DOI: https://doi.org/10.1016/j.jvir.2016.12.849

IF: 3.682

2017-01-01

Journal of Vascular and Interventional Radiology

Abstract:To evaluate the feasibility and safety of using intrabiliary radiofrequency hyperthermia (RFH) to enhance local chemotherapeutic drug deposit in bile duct walls of survival pigs with a needle-integrated balloon catheter Twelve pigs were randomly allocated into two survival study groups: (i) five pigs received intrabiliary chemodrug delivery alone; and (ii) five pigs received a combination of intrabiliary chemotherapeutic drugs plus RFH at 42 ℃. Via a transcholecystic approach and under fluoroscopy guidance, a mixture of 10mg 5-fluouracil (5-FU) and 125μg motexafin gadolinium (MGd) was injected into common bile duct wall through a needle-integrated balloon catheter (Mercator Medsystem). Then, pigs were kept alive for 24 hours. 5-FUs in bile duct tissues were extracted and quantified using high performance liquid chromatography (HPLC). The harvested bile duct tissues were further assessed by optical imaging and confocal microscopy to confirm the penetration and distribution of MGd in bile duct walls. Subsequent histology was used to correlate imaging findings and examine potential bile duct injuries. The quantities of 5-FU in two groups were statistically compared. All pigs survived very well without any abnormalities of vital signs. Immediate cholangiograms after intrabiliary chemotherapeutic drug injection and RFH showed no extravasation of agents outside bile duct lumens. Histology confirmed no bile duct injuries. HPLC analysis demonstrated a higher content of 5-FU in bile ducts treated with intrabiliary injection of chemotherapeutic drugs and RFH, compared to bile ducts with injection of 5-FU alone ( 5-FU, 6.4 ± 0.19mg VS 2.7 ± 0.21mg, P<0.0001), which indicates RFH can enhance the deposit of 5-FU in pig bile duct tissues. Optical imaging and confocal microscopy further confirmed diffusive fluorescence of MGd throughout bile walls. It is safe and effective using intrabiliary RFH to enhance the deposit of intrabiliarily delivered chemotherapeutics with a needle-integrated balloon catheter, which provides an alternative to treat pancreatobiliary malignancies. (supported by an NIH RO1EBO12467).
Regional intra-arterial vs. systemic chemotherapy for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis

Yanjie Cao,Dedong Yu,Yun Wu,Wei Zhu

DOI: https://doi.org/10.3389/fonc.2024.1197424

IF: 4.7

2024-04-08

Frontiers in Oncology

Abstract:Introduction: Pancreatic cancer is a highly aggressive malignancy with limited response to chemotherapy. This research aims to compare the effectiveness and safety of regional intra-arterial chemotherapy (RIAC) with conventional systemic chemotherapy in treating advanced stages of pancreatic cancer. Methods: A comprehensive literature review was conducted using databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Studies assessing the comparative outcomes of RIAC and systemic chemotherapy were included. Data extraction and quality evaluation were performed independently by two researchers. Statistical analysis was conducted using STATA16 software, calculating odds ratios (OR), risk differences (RD), and 95% confidence intervals (CI). Results: Eleven studies, comprising a total of 627 patients, were included in the meta-analysis. The findings showed that patients undergoing RIAC had significantly higher rates of partial remission (PR) compared to those receiving systemic chemotherapy (OR = 2.23, 95% CI: 1.57, 3.15, I2= 0%). Additionally, the rate of complications was lower in the RIAC group (OR = 0.45, 95% CI: 0.33, 0.63, I2= 0%). Moreover, patients treated with RIAC had notably longer median survival times. Discussion: The results of this research indicate that RIAC is associated with a higher rate of partial remission, improved clinical benefits, and fewer complications compared to systemic chemotherapy in the management of advanced pancreatic cancer. These findings suggest that RIAC may be a more effective and safer treatment option for patients with advanced stages of pancreatic cancer. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023404637.

oncology
Result Analysis of Clinical Treatment of Advanced Pancreatic Carcinoma in Patients Undergoing Regional Chemotherapy

Thomas Höhler,Ludger Staib,Helmut Oettle

2002-01-01

Abstract:Objective:To observe the outcome of clinical treatment of advanced pancreatic carcinoma in patients who were unable to bear surgery and underwhent regional chemotherapy.Methods:42patients who were diagnosed through exploration of pancreatic carcinoma that could not be treated by radical re-section were given regional chemotherapy.Through laparotomy a catheter was inserted into the gastroduo-denal artery or right gastroepiploic artery and a bolus of 5-FU at the dose of 1g was infused through the catheter during operation.5-FU at the dose of 1g was infused during weekly after operation.Results:No severe complications or side effects were found in any patient,most symptoms were relieved or disappeared,the middle survival time rose to8.2months (P0.05),and the serum concentration of CA19-9became lower than that before the therapy.Conclusion:Regional chemotherapy has advantages of fewer side effects and complications,and can relieve clinical symptoms and prolong survival time.
Intrabiliary RF Heat-Enhanced Local Chemotherapy of a Cholangiocarcinoma Cell Line: Monitoring with Dual-Modality Imaging--preclinical Study.

Feng Zhang,Thomas Le,Xia Wu,Han Wang,Tong Zhang,Yanfeng Meng,Baojie Wei,Stephanie S. Soriano,Patrick Willis,Orpheus Kolokythas,Xiaoming Yang

DOI: https://doi.org/10.1148/radiol.13130866

IF: 19.7

2014-01-01

Radiology

Abstract:PURPOSE:To determine whether magnetic resonance (MR) imaging heating guidewire-mediated radiofrequency (RF) hyperthermia could enhance the therapeutic effect of gemcitabine and 5-fluorouracil (5-FU) in a cholangiocarcinoma cell line and local deposit doses of chemotherapeutic drugs in swine common bile duct (CBD) walls.MATERIALS AND METHODS:The animal protocol was approved by the institutional animal care and use committee. Green fluorescent protein-labeled human cholangiocarcinoma cells and cholangiocarcinomas in 24 mice were treated with (a) combination therapy with chemotherapy (gemcitabine and 5-FU) plus RF hyperthermia, (b) chemotherapy only, (c) RF hyperthermia only, or (d) phosphate-buffered saline. Cell proliferation was quantified, and tumor changes over time were monitored with 14.0-T MR imaging and optical imaging. To enable further validation of technical feasibility, intrabiliary local delivery of gemcitabine and 5-FU was performed by using a microporous balloon with (eight pigs) or without (eight pigs) RF hyperthermia. Chemotherapy deposit doses in the bile duct walls were quantified by means of high-pressure liquid chromatography. The nonparametric Mann-Whitney U test and the paired-sample Wilcoxon signed rank test were used for data analysis.RESULTS:Combination therapy induced lower mean levels of cell proliferation than chemotherapy only and RF hyperthermia only (0.39 ± 0.13 [standard deviation] vs 0.87 ± 0.10 and 1.03 ± 0.13, P < .001). Combination therapy resulted in smaller relative tumor volume than chemotherapy only and RF hyperthermia only (0.65 ± 0.03 vs 1.30 ± 0.021 and 1.37 ± 0.05, P = .001). Only in the combination therapy group did both MR imaging and optical imaging show substantial decreases in apparent diffusion coefficients and fluorescent signals in tumor masses immediately after the treatments. Chemotherapy quantification showed a higher average drug deposit dose in swine CBD walls with intrabiliary RF hyperthermia than without it (gemcitabine: 0.32 mg/g of tissue ± 0.033 vs 0.260 mg/g ± 0.030 and 5-FU: 0.660 mg/g ± 0.060 vs 0.52 mg/g ± 0.050, P < .05).CONCLUSION:The use of intrabiliary MR imaging heating guidewire-mediated RF hyperthermia can enhance the chemotherapeutic effect on a human cholangiocarcinoma cell line and local drug deposition in swine CBD tissues.
A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization

H Homma,T Doi,S Mezawa,K Takada,T Kukitsu,T Oku,T Akiyama,T Kusakabe,K Miyanishi,Y Niitsu

IF: 6.9209

2000-07-15

Cancer

Abstract:Background: Patients with American Joint Committee on Cancer Stage IV advanced pancreatic carcinoma have been treated by systemic chemotherapy, intraarterial chemotherapy, radiation therapy, and multidisciplinary treatment using a combination of these. However, the outcome has not always been satisfactory. In the current study the authors describe the method and results of a new chemotherapy for advanced pancreatic carcinoma. Methods: To restrict the blood flow into the pancreas (mainly to the great pancreatic artery and the caudal pancreatic artery), the peripancreatic blood vessels were embolized superselectively with microcoils. In 31 patients with advanced pancreatic carcinoma, the catheter tip for the arterial infusion chemotherapy was placed in the splenic artery just proximal to the branching of the great pancreatic artery when the treatment was given for primary tumors, and in the common hepatic artery when the treatment was given for a metastatic liver lesion. The other end of the catheter was connected to an implanted injection port embedded in the femoral region, and 5-fluorouracil and cisplatin were administered by continuous arterial infusion. Results: Of the 31 patients with advanced pancreatic carcinoma, 23 (74%) underwent hemodynamic change and arterial infusion chemotherapy, with a response rate of 73.9% (complete response rate of 8.7% and a partial response rate of 65.2%) and a mean survival period of 18.26 +/- 10.06 months. The 1-year, 2-year, and 3-year survival rates were 90.9%, 42. 8%, and 18.3%, respectively, with a mean survival period of 19.0 months. Of these 23 patients, the 16 patients with liver metastases had a response rate of 68.8% and a mean survival period of 16.25 +/- 8.35 months, whereas the 7 patients without liver metastases had a response rate of 87.5% and a mean survival period of 22.86 +/- 12.69 months. Conclusions: In patients with Stage IV advanced pancreatic carcinoma, arterial infusion chemotherapy after hemodynamic change was found to be effective against both primary tumors and metastatic liver lesions. The authors believe that the treatment presented in the current study should be attempted, even in patients with advanced pancreatic carcinoma, as long as the blood vessels for vascular supply distribution exist.
Transarterial Infusion with Gemcitabine and Oxaliplatin for the Treatment of Unresectable Pancreatic Cancer

Yi Chen,Xiao-Lin Wang,Jian-Hua Wang,Zhi-Ping Yan,Jie-Min Cheng,Gao-Quan Gong,Ling-Xiao Liu,Guo-Ping Li,Chang-Yu Li

DOI: https://doi.org/10.1097/cad.0000000000000120

2014-01-01

Anti-Cancer Drugs

Abstract:The aim of this study was to evaluate the therapeutic efficacy and the safety of transarterial infusion (TAI) with gemcitabine and oxaliplatin in patients with unresectable pancreatic cancer (PC). After celiac arteriogram and super-mesenteric arteriography, 1000mg/m(2) gemcitabine and 100mg/m(2) oxaliplatin were infused through 4- or 5-Fr catheters in arteries supplying blood to the tumor. In cases in which the blood-supplying artery could be selectively catheterized, the infusion was performed through a 3-Fr catheter placed in the tumor-supplying artery. Therapeutic courses were repeated every 4 weeks. The tumor response, the overall survival, and adverse effects were monitored. Thirty-two patients with unresectable PC were enrolled in this study, including 20 male and 12 female patients. A total of 105 cycles of TAI (mean=3.3 cycles/patient) were performed. Of 32 patients, partial remission was achieved in eight (25.0%), stable disease in 13 (40.6%), and progressive disease in 11 (34.4%). The overall response rate was 25.0%. The median survival time was 10.0 months (range = 4-21 months). Grade III-IV toxicity, vomiting, occurred with a rate of 21.9%. Grade I-II neutropenia, thrombocytopenia, peripheral nerve toxicity, elevated serum transaminases levels, and serum total bilirubin were observed. TAI with gemcitabine and oxaliplatin is well tolerated and highly effective in patients with unresectable PC. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Intensity Modulated Radiation Therapy and Chemotherapy for Locally Advanced Pancreatic Cancer: Results of Feasibility Study

YR Bai,GH Wu,WJ Guo,XD Wu,Y Yao,Y Chen,RH Zhou,DQ Lu

DOI: https://doi.org/10.3748/wjg.v9.i11.2561

IF: 5.374

2003-01-01

World Journal of Gastroenterology

Abstract:AIM: To explore whether intensity modulated radiation therapy (IMRT) in combination with chemotherapy could increase radiation dose to gross tumor volume without severe acute radiation related toxicity by decreasing the dose to the surrounding normal tissue in patients with locally advanced pancreatic cancer.METHODS: Twenty-one patients with locally advanced pancreatic cancer were evaluated in this clinical trial. Patients would receive the dose of IMRT from 21Gy to 30Gy in 7 to 10 fractions within two weeks after conventional radiotherapy of 30Gy in 15 fractions over 3 weeks. The total escalation tumor dose would be 51, 54, 57, 60Gy, respectively. 5-fluororacil (5-FU) or gemcitabine was given concurrently with radiotherapy during the treatment course.RESULTS: Sixteen patients who had completed the radiotherapy plan with doses of 51Gy (3 cases), 54Gy (3 cases), 57Gy (3 cases) and 60Gy (7 cases) were included for evaluation. The median levels of CA19-9 prior to and after radiotherapy were 716 U/ml and 255 U/ml respectively (P<0.001) in 13 patients who demonstrated high levels of CA19-9 before radiotherapy. Fourteen patients who suffered from pain could reduce at least 1/3-1/2 amount of analgesic intake and 5 among these patients got complete relief of pain. Ten patients improved in Karnofsky performance status (KPS). The median follow-up period was 8 months and one-year survival rate was 35 %. No patient suffered more than grade III acute toxicities induced by radiotherapy.CONCLUSION: Sixty Gy in 25 fractions over 5 weeks with late course IMRT technique combined with concurrent 5-FU chemotherapy can provide a definitely palliative benefit with tolerable acute radiation related toxicity for patients with advanced pancreatic cancer.
Prostate cancer: correlation of MR images with tissue optical density at pathologic examination.

L. Quint,J. V. Van Erp,P. Bland,E. A. Del Buono,S. Mandell,H. Grossman,P. Gikas

DOI: https://doi.org/10.1148/RADIOLOGY.179.3.2028002

IF: 19.7

1991-06-01

Radiology

Abstract:To explain the variability in detection of prostate cancer with magnetic resonance (MR) imaging, the authors correlated preoperative MR findings in 28 patients with tissue optical density (TOD) measurements on whole-mount pathologic slides prepared from radical prostatectomy specimens. TOD was used as an indicator of the degree of tissue compactness or openness. TOD measurements from proved cancers and from pathologic regions corresponding to MR lesions (areas of low signal intensity seen at T2-weighted MR imaging) were compared with TOD measurements from adjacent, nonmalignant tissue. TOD measurements corresponding to MR lesions were higher than noncancerous tissue measurements in all cases (P less than .005). Although most of these lesions represented cancers (21 of 30), nine of 30 represented benign tissue that was composed mainly of densely packed fibromuscular stroma (30% false-positive results). Thus, signal intensity appeared to be related to TOD rather than to a specific histologic tissue type, and the finding of a peripheral zone lesion with low signal intensity did not necessarily indicate the presence of a cancer.
Study of Curative Effect of Infusion Gemcitabine Via Artery for 103 Cases with Advanced Cancer

徐卫东,陈世晞,方婕,吴建达,吴美琦,尹国文,席玮,陈骏

DOI: https://doi.org/10.3969/j.issn.1006-6233.2003.10.003

2003-01-01

Abstract:Objective: To observe the efficacy of infusion gemcitabine via artery for advanced cancer. Methods:103 cases advanced cancer proved by pathology,received the chemotherapy combining gemciabine plus IL-2 infused into artery , in some stage of course. Results: In 68 pancreatic cancer,the obvious improvement in pain was 29.4%,the duration of clinical benefit responses was 19.2 weeks, the survival rate was 45.6%,23.5%,17.6%, with median survival of 7.13,6,9,12 months. In 11 gallbladder cancer, the obvious improvement in pain was 27.2%, the duration of CBR was 18.8 weeks, the survival rates was 54.5%,27.3%,18.2% with median survival of 7.45,6 ,9,12months. The response rate was 62.5% in 8 non-small cell lung cancer, 1 year survival rate was 37.5%.In 6 eolorectal cancer and 7 liver cancer,the response rates was 83.3% and 85.7% . 1,2 years survival rates was 66.7% , 33.3% and 71.4% , 42.9%. Conclusions: Infusion gemcitabine via artery can not only prolong survival rate but also improve life of quality.
Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, randomized controlled trial comparing with intravenous chemotherapy

Changjing Huang,Chien-Shan Cheng,Yehua Shen,Hao Chen,Junhua Lin,Yongqiang Hua,Lanyun Feng,Caijun Wu,Peng Wang,Zhen Chen,Zhiqiang Meng

DOI: https://doi.org/10.1186/s12885-024-12695-8

IF: 4.638

2024-08-02

BMC Cancer

Abstract:Background: Advanced pancreatic adenocarcinoma lacks effective treatment options, and systemic gemcitabine-based chemotherapy offers only marginal survival benefits at the cost of significant toxicities and adverse events. New therapeutic options with better drug availability are warranted. This study aims to evaluate the safety and efficacy of digital subtraction angiography (DSA)-guided pancreatic arterial infusion (PAI) versus intravenous chemotherapy (IVC) using the gemcitabine and oxaliplatin (GEMOX) regimen in unresectable locally advanced or metastatic pancreatic cancer (PC) patients. Materials and methods: This study prospectively enrolled 51 eligible treatment-naive patients with unresectable PC to receive GEMOX treatment via PAI or IVC (1:1 ratio randomization) from December 2015 to December 2019. Cycles were repeated monthly, and each process consisted of two treatments administered bi-weekly. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), 1-year survival, 6-month survival, tumor-site subgroup survival, and incidences of adverse events were compared. Results: The median OS of the PAI and IVC groups were 9.93 months and 10.07 months, respectively (p = 0.3049). The median PFS of the PAI and IVC groups were 5.07 months and 4.23 months (p = 0.1088). No significant differences were found in the ORR (11.54% vs. 4%, p = 0.6312), DCR (53.85% vs. 44%, p = 0.482), and 1-year OS rate (44% vs. 20.92%, p = 0.27) in PAI and IVC groups. The 6-month OS rate was significantly higher in the PAI group (100%) than in the IVC group (83.67%) (p = 0.0173). The median OS of patients in PAI group with pancreatic head and neck tumors were significantly higher than those of body and tail tumors (12.867 months vs. 9 months, p = 0.0214). The incidences of hematologic disorders, liver function disorders, and digestive disorders in the IVC group were higher than in the PAI group (p < 0.05). Conclusion: GEMOX PAI therapy presented a higher 6-month OS rate and fewer adverse events than IVC in advanced pancreatic adenocarcinoma patients. Those with pancreatic head and neck tumors may yield a superior treatment outcome from PAI treatment. Trial registration number: NCT02635971. Date of registration: 21/12/2015.
Effects of Chemotherapy Via Regional Arterial Perfasion on Lymph Node Metastasis of Pancreatic Cancer

XU Wen-yan,FU De-liang

DOI: https://doi.org/10.3760/cma.j.issn.1007-8118.2010.03.028

2010-01-01

Abstract:Regional arterial intra-chemotherapy (RAIC) was an effective method of combined therapy for pancreatic carcinoma, which could elevate the regional con-centration of anticancer agents for sufficient dosage in pan-creas, reduce the systemic adverse events, increase the toler-ation of chemotherapy.It could also increase the concentra-tion of anticancer agents in regional lymph node of pancreas, thus decrease the lymph node metastasis.The mechanism of RAIC for pancreatic cancer and the impact for lymph node metastasis needed to be further investigated.
Effects of Preoperative Regional Intra-Arterial Chemotherapy on Lymphatic Metastasis of Pancreatic Head Carcinoma

YAO Lie,ZHANG Bo,LONG Jiang,FU De-liang,JIN Chen,JIANC Yong-jian,TANG Feng,NI Quan-xing

DOI: https://doi.org/10.3760/cma.j.issn.1673-9752.2009.04.007

2009-01-01

Abstract:Objective To evaluate the efficacy of preoperative regional intra-arterial chemotherapy (RIAC) in the treatment of resectable pancreatic head carcinoma. Methods The clinical data of 50 patients with resectable pancreatic head carcinoma who had been admitted to the Research Institute of Pancreatic Diseases of Fudan University from December 2006 to July 2007 were retrospectively analyzed. Patients were randomly divided into2 groups (n =25 in each group): patients in group A were treated with preoperative RIAC followed by regional pancreaticoduodenectomy, and patients in group B were treated with surgical procedure routinely. The lymphatic metastases in the 50 specimens of pancreatic head carcinoma were detected by histological examination with hematoxylin and eosin (HE) staining, and lymphatic micrometastases were detected by immunohistochemical method with staining of cytokeratin AE1/AE3 in 10 specimens with negative HE staining of the lymph nodes in each group. Results There was no significant difference in the incidence of complications, the length of hospital stay and the 1-, 2-year survival rates between the 2 groups (χ2 = 0.12, 2.88, P > 0.05). The incidence of positive lymph node metastasis in group A was 7.1% (52/734), which was significantly higher than 22.1% (118/532) in group B (χ2 = 60.01, P < 0.05). The incidence of lymphatic micrometastasis was 9.4% (30/319) in group A, and 9.1% (23/252) in group B, with no statistical difference between the 2 groups (χ2= 0.01, P > 0.05). Conclusions Preoperative RIAC is helpful in improving the prognosis of patients with resectable pancreatic head carcinoma by reducing the incidence of lymphatic metastasis and decreasing tumor stage.
Preparation of Bovine Serum Albumin Nanoparticles Loaded with Gemcitabine and the Cytotoxic Effect on Pancreatic Cancer Cells in Vitro

LI Jin-ming,CHEN Wei,LONG Jiang,JIN Chen,LU Wei-yue,NI Quan-xing,FU De-liang,HOU Hui-min

DOI: https://doi.org/10.3760/cma.j.issn.1674-1935.2008.05.004

2008-01-01

Abstract:Objectives To investigate preparation of gemcitabine albumin nanoparticles, and its property of slow-release, the cytotoxic effect on pancreatic cancer cells (PANC1) in vitro, for improving the effect of regional intra-arterial infusion chemotherapy in pancreatic cancer with new medicament in the future. Methods The gemcitabine albumin nanoparticles were prepared with bovine serum albumin and gemcitabine with the desolvation-crosslink method, the concentration of gemcitabine was detected by high performance liquid chromatography (HPLC). The cytotoxic effect on pancreatic cancer cells in vitro were detected with MTT colorimetric assay. Results The mean diameter of gemcitabine albumin nanoparticles was (156.2±2.2) nm, and Zeta potential was (-20.4±1.41)mV, drug loading was 10.8%, drug release time in virto was 3 hours respectively. Gemcitabine albumin nanoparticles (0.01～50 μg/ml) had a 31%～44% inhibitory rate on PANC1 cell, which was similar to the inhibitory rate of same concentration of gemcitabine (26%～47%). Conclusions The new preparation of gemcitabine albumin nanoparticles had obvious drug slow-release effect, which may help improve the effect of regional intra-arterial infusion chemotherapy for pancreatic cancer.

Effect of preeclampsia on placental function: influence of sexual dimorphism, microRNA's and mitochondria.

Analysis of the Efficacy of Transcatheter Arterial Infusion Chemotherapy in the Treatment of Pancreatic Carcinoma

Intratumoral Radiofrequency Hyperthermia-Enhanced Direct Chemotherapy of Pancreatic Cancer

A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Treatment of Advanced Pancreatic Cancer by Transarterial Infusion of Gemcitabine

A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer

Diffusion‐weighted MRI Monitoring of Pancreatic Cancer Response to Radiofrequency Heat‐enhanced Intratumor Chemotherapy

The Underlying Molecular Mechanism of Intratumoral Radiofrequency Hyperthermia-Enhanced Chemotherapy of Pancreatic Cancer

Intrabiliary Radiofrequency-Enhanced Local Chemotherapeutic Deposit in Bile Duct Walls Using a Needle-Integrated Balloon Catheter: A Feasibility Study on Survival Pigs

Regional intra-arterial vs. systemic chemotherapy for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis

Result Analysis of Clinical Treatment of Advanced Pancreatic Carcinoma in Patients Undergoing Regional Chemotherapy

Intrabiliary RF Heat-Enhanced Local Chemotherapy of a Cholangiocarcinoma Cell Line: Monitoring with Dual-Modality Imaging--preclinical Study.

A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization

Transarterial Infusion with Gemcitabine and Oxaliplatin for the Treatment of Unresectable Pancreatic Cancer

Intensity Modulated Radiation Therapy and Chemotherapy for Locally Advanced Pancreatic Cancer: Results of Feasibility Study

Prostate cancer: correlation of MR images with tissue optical density at pathologic examination.

Study of Curative Effect of Infusion Gemcitabine Via Artery for 103 Cases with Advanced Cancer

Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, randomized controlled trial comparing with intravenous chemotherapy

Effects of Chemotherapy Via Regional Arterial Perfasion on Lymph Node Metastasis of Pancreatic Cancer

Effects of Preoperative Regional Intra-Arterial Chemotherapy on Lymphatic Metastasis of Pancreatic Head Carcinoma

Preparation of Bovine Serum Albumin Nanoparticles Loaded with Gemcitabine and the Cytotoxic Effect on Pancreatic Cancer Cells in Vitro